Ipsen S.A. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Ipsen S.A. - Product Pipeline Review - 2016', provides an overview of the Ipsen S.A.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Ipsen S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Ipsen S.A. - The report provides overview of Ipsen S.A. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Ipsen S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Ipsen S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Ipsen S.A.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ipsen S.A. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ipsen S.A.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Ipsen S.A. Snapshot 7 Ipsen S.A. Overview 7 Key Information 7 Key Facts 7 Ipsen S.A. - Research and Development Overview 8 Key Therapeutic Areas 8 Ipsen S.A. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Ipsen S.A. - Pipeline Products Glance 17 Ipsen S.A. - Late Stage Pipeline Products 17 Pre-Registration Products/Combination Treatment Modalities 17 Phase III Products/Combination Treatment Modalities 18 Ipsen S.A. - Clinical Stage Pipeline Products 19 Phase II Products/Combination Treatment Modalities 19 Phase I Products/Combination Treatment Modalities 20 Phase 0 Products/Combination Treatment Modalities 21 Ipsen S.A. - Early Stage Pipeline Products 22 Preclinical Products/Combination Treatment Modalities 22 Discovery Products/Combination Treatment Modalities 23 Ipsen S.A. - Drug Profiles 24 lanreotide acetate 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 abobotulinumtoxin A 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 abobotulinumtoxin A next generation 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 triptorelin pamoate PR 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BN-82451 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BIM-23A758 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 3BP-227 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Peptides for Endocrine Gland Disorders 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Peptides for Oncology and Genito Urinary System And Sex Hormones 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Peptides to Antagonize ACTH Receptor for Cushing's Syndrome 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Recombinant Protein 1 to Inhibit SNARE for Neurology 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Recombinant Protein 1 to Target SNAP-25 for Movement Disorders 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Recombinant Protein 2 to Inhibit SNARE for Neurology 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Recombinant Protein 3 to Target SNAP-25 for Movement Disorders 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 STX-140 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 STX-681 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 SXN-101742 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 SXN-101959 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Drugs to Antagonize Androgen Receptor for Prostate Cancer 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Peptides for Endocrine Disease 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Recombinant Protein 2 to Target SNAP-25 for Movement Disorders 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Recombinant Protein 4 to Target SNAP-25 for Movement Disorders 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Ipsen S.A. - Pipeline Analysis 49 Ipsen S.A. - Pipeline Products by Target 49 Ipsen S.A. - Pipeline Products by Route of Administration 51 Ipsen S.A. - Pipeline Products by Molecule Type 52 Ipsen S.A. - Pipeline Products by Mechanism of Action 53 Ipsen S.A. - Recent Pipeline Updates 54 Ipsen S.A. - Dormant Projects 61 Ipsen S.A. - Discontinued Pipeline Products 62 Discontinued Pipeline Product Profiles 62 BIM-23A760 62 (mecasermin + somatropin) 62 irosustat 62 taspoglutide 62 Ipsen S.A. - Company Statement 63 Ipsen S.A. - Locations And Subsidiaries 64 Head Office 64 Other Locations & Subsidiaries 64 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Ipsen S.A., Key Information 7 Ipsen S.A., Key Facts 7 Ipsen S.A. - Pipeline by Indication, 2016 9 Ipsen S.A. - Pipeline by Stage of Development, 2016 11 Ipsen S.A. - Monotherapy Products in Pipeline, 2016 12 Ipsen S.A. - Partnered Products in Pipeline, 2016 13 Ipsen S.A. - Partnered Products/ Combination Treatment Modalities, 2016 14 Ipsen S.A. - Out-Licensed Products in Pipeline, 2016 15 Ipsen S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16 Ipsen S.A. - Pre-Registration, 2016 17 Ipsen S.A. - Phase III, 2016 18 Ipsen S.A. - Phase II, 2016 19 Ipsen S.A. - Phase I, 2016 20 Ipsen S.A. - Phase 0, 2016 21 Ipsen S.A. - Preclinical, 2016 22 Ipsen S.A. - Discovery, 2016 23 Ipsen S.A. - Pipeline by Target, 2016 49 Ipsen S.A. - Pipeline by Route of Administration, 2016 51 Ipsen S.A. - Pipeline by Molecule Type, 2016 52 Ipsen S.A. - Pipeline Products by Mechanism of Action, 2016 53 Ipsen S.A. - Recent Pipeline Updates, 2016 54 Ipsen S.A. - Dormant Developmental Projects,2016 61 Ipsen S.A. - Discontinued Pipeline Products, 2016 62 Ipsen S.A., Subsidiaries 64
List of Figures
Ipsen S.A. - Pipeline by Top 10 Indication, 2016 9 Ipsen S.A. - Pipeline by Stage of Development, 2016 11 Ipsen S.A. - Monotherapy Products in Pipeline, 2016 12 Ipsen S.A. - Partnered Products in Pipeline, 2016 13 Ipsen S.A. - Out-Licensed Products in Pipeline, 2016 15 Ipsen S.A. - Pipeline by Top 10 Target, 2016 49 Ipsen S.A. - Pipeline by Route of Administration, 2016 51 Ipsen S.A. - Pipeline by Molecule Type, 2016 52 Ipsen S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016 53
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and productRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.